Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230011/S002

TruSight Oncology Comprehensive

Illumina, Inc. · Decision date Jun 26, 2026

FDA DECISIONP230011/S002

What did the FDA approve?

FDA records P230011/S002 as a supplement to PMA P230011, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jun 26, 2026.

FDA approval order statement

TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multi- nucleotide variants, insertions, and deletions from DNA, and fusions in 24 genes and splice variants in one gene from RNA. The test also reports a Tumor Mutational Burden (TMB) score and Microsatellite Instability (MSI) status. The test is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the targeted therapies listed in Table 1, in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 of the intended use statement are not conclusive or prescriptive for labeled use of any specific therapeutic product.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Jun 26, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230011/S002
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Jun 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P230011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230011 · Original PMA

    TruSight Oncology Comprehensive

  2. P230011/S002 received

    Application receipt date recorded by FDA.

  3. P230011/S004 · Related supplement

    TruSight Oncology Comprehensive

  4. P230011/S005 · Related supplement

    TruSight Oncology Comprehensive

  5. P230011/S007 · Related supplement

    TruSight Oncology Comprehensive

  6. P230011/S002 · FDA decision

    Normal 180 Day Track

  7. P230011/S006 · Related supplement

    TruSight Oncology Comprehensive

  8. P230011/S008 · Related supplement

    TruSight Oncology Comprehensive

Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230011

Product / regulatory recordCompanyPathwayDecision dateSource
Illumina, Inc.PMA approvalAug 21, 2024FDA
Illumina, Inc.PMA supplementSep 5, 2025FDA
Illumina, Inc.PMA supplementSep 19, 2025FDA
Illumina, Inc.PMA supplementApr 23, 2026FDA
Illumina, Inc.PMA supplementAug 14, 2026FDA
Illumina, Inc.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Illumina, Inc.

Headquarters
Not reported
Brand website
illumina.com
FDA applicant address
5200 Illumina Way, San Diego, CA, 92122

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records